Pacira BioSciences, Inc. (PCRX) earnings date, results and what the price requires

    Nasdaq · SEC CIK 0001396814 · SEC filings checked Oct 17, 2026

    Next report
    Nov 9, 2026
    Estimated from reporting history (96-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
    Last close
    $36.34
    Polygon.io daily close, Oct 16, 2026. End of day, not live.
    Trailing diluted EPS
    $0.36
    Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025 · P/E 100.9

    Previous results (SEC filings)

    Quarter endedReportedRevenueNet incomeDiluted EPSSource
    Jun 30, 2026Aug 4, 2026$192.4M$4.7M$0.12Filing
    Mar 31, 2026Apr 30, 2026$177.4M$2.9M$0.07Filing
    Dec 31, 2025Feb 26, 2026$196.9M$1.6M$0.05Filing
    Sep 30, 2025Nov 6, 2025$179.5M$5.4M$0.12Filing
    Jun 30, 2025Aug 5, 2025$181.1M$-4.8M$-0.11Filing
    Mar 31, 2025May 8, 2025$168.9M$4.8M$0.10Filing
    Dec 31, 2024Jan 10, 2025$187.3M$16.0M$0.38Filing
    Sep 30, 2024Nov 6, 2024$168.6M$-143.5M$-3.11Filing

    What would Pacira BioSciences, Inc. have to report for its valuation to change?

    At $36.34, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 53.9% a year, to $3.11. On that path the next quarter needs diluted EPS near $0.18, against $0.12 in the quarter ended Sep 30, 2025.

    Are you considering buying, or do you already own shares?

    Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.

    ResultOriginalYours
    Required EPS growth / year53.9%53.9%
    EPS needed in final year$3.11$3.11

    Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.

    Prepare for earnings across my investments — $399/month

    Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. PCRX goes in with your buy-or-wait comparison and assumptions preserved.

    Start Desk — $399/month

    Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.